(On to v1.0.6 of the Cyoforin doc.)
Testing has revealed that the pseudocyetin-ω formulation implant, over time, has the unintended side effect of causing spontaneous biosynthesis of even more pseudocyetin-ω formulation.
It is transferable to others through the subject's bodily fluids – like milk, or semen – and due to it having to be activated, it can take a long time to detect secondary exposure.
The fact that it causes spontaneous production of more pseudocyetin-ω, during active gestation or tocolysis, also means that the presence of the implant doesn't matter for those subjected to secondary exposure, and also that it can take a long time to clear the subject's system, if they keep getting activated right after the end of a cycle; for this reason, a nullification agent had to be devised, to flush pseudocyetin-ω out.
Likewise, the spontaneous increase of pseudocyetin-ω in the subject's system, beyond what the implants are designed to dispense, makes dosing unpredictable, with a high likelihood of excessive polypseudocyesis (equivalent of gestating 8+ fetuses); modifications will need to be made to how it is dosed and activated, with this in mind.
Two new variants of pseudocyetin-ω were created, for testing purposes:
pseudocyetin-ω-2 is asymptomatic in the primary subject, and only serves to cause small-scale spontaneous biosynthesis of pseudocyetin-ω – the purpose was to find out if the spontaneous biosynthesis could be isolated, and if it was capable of reproducing other variants, which as it turns out, it is; the lack of gestation means that once the implant is removed, pseudocyetin-ω-2 leaves the system in a matter of days. The pseudocyetin-ω reproduced by it, however, does not, and if activated will result in subsequent gestation.
pseudocyetin-ω-3 is asymptomatic on its own, but combined with other formulations will induce biosynthetic reproduction of that variant, during active gestation or tocolysis.
The original pseudocyetin-ω formulation is pending alterations, to solve the issue of unintentional overdosing; currently, engineering a maximum number of activations per cycle, and/or modifying the formulation with additives which reduce the discomfort of excessive polypseudocyesis, is being considered.
Removing the biosynthesis aspect from the formulation entirely was also considered, though it may end up a variant of its own, rather than replacing the original.
